血清VEGF、TRACP-5b含量分析对肺癌骨转移患者的检测意义

The clinical value of serum VEGF and TRACP-5b as markers to diagnose bone metastases in lung carcinoma patients

背景与目的:肺癌易发生骨转移,本研究旨在探讨肺癌患者血清中血管内皮生长因子(vascular endothelial growth factor,VEGF)与抗酒石酸酸性磷酸酶5b(tartrate-resistant acid phosphatase 5b,TRACP-5b)两者表达对肺癌骨转移的诊断意义。方法:酶联免疫吸附试验(ELISA)检测72例肺癌患者血清VEGF及TRACP-5b的表达水平,比较ECT全身骨显像诊断为骨转移和未出现骨转移两组患者中VEGF和TRACP-5b的血清水平。结果:28例肺癌患者骨ECT诊断为多发性骨转移,这组患者血清VEGF含量平均为342.85 pg/mL;血清TRACP-5b含量平均为5.45 pg/mL;44例患者骨扫描阴性或不确定,血清VEGF含量平均为234.55 pg/mL;TRACP-5b含量平均为3.93 pg/mL,两者相比差异有统计学意义(P<0.05)。骨扫描与血清学VEGF和TRACP-5b检查对骨转移的检测效果经McNemar检验显示两者相似。结论:肺癌患者发生骨转移时,血清VEGF与TRACP-5b含量明显增高,取材及检测方便,可作为肺癌患者判断骨转移及监测病情演变的指标之一。

Background and purpose:Bone metastasis is easy to occur in lung cancer.This study was aimed to explore the serum levels in vascular endothelial growth factor(VEGF) and tartrate-resistant acid phosphatase 5b(TRACP-5b) and analyze the clinical value of diagnosing bone metastases in lung carcinoma patients.Methods:VEGF and TRACP-5b levels in the serum of 72 lung carcinoma patients were determined using enzyme linked-immunosorbent assay(ELISA).These patients were then divided into 2 groups,with and without bone metastases groups,by ECT examination.Results:The serum levels of VEGF and TRACP-5b in 28 patients with bone metastases were 342.85 and 5.45 pg/mL,whereas the serum levels of VEGF and TRACP-5b in 44 patients without bone metastases were 234.55 and 3.93 pg/mL.There were significant differences between these 2 groups(P<0.05).Positive correlations were found between VEGF and TRACP-5b by ECT examination.Conclusion:The serum levels of VEGF and TRACP-5b were high in lung carcinoma patients who had bone metastases.This may be helpful in diagnosing bone metastases of carcinoma patients.